Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, phase 3 assessing efficacy of dose escalation to UPA 30 mg QD (UPA30) among patients who demonstrated an inadequate response to UPA 15 mg QD (UPA15) during the long-term extension (LTE) study

Next Previous
Trial Profile

An open label, phase 3 assessing efficacy of dose escalation to UPA 30 mg QD (UPA30) among patients who demonstrated an inadequate response to UPA 15 mg QD (UPA15) during the long-term extension (LTE) study

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms LTE U-ACTIVATE; U-ACTIVATE

Most Recent Events

  • 19 Feb 2024 According to AbbVie Media Release, data from the study will be presented at the 19th Congress of European Crohn's and Colitis Organisation (ECCO) taking place in Stockholm, Sweden from February 21-24.
  • 17 Oct 2023 Interim Results (n=238) assessing efficacy and safety data from patients receiving continuous therapy with UPA15 or UPA30 for 1 year in the maintenance study, and an additional 48 weeks (approximately 2 years in total) in the ongoing, 288-week, long-term extension (LTE) study presented at the 31st United European Gastroenterology Week
  • 10 Oct 2023 According to AbbVie Media Release, interim results from this trial will be presented at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from Oct 14-17.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top